A Patch Wearable Cardioverter-Defibrillator for Patients at Risk of Sudden Cardiac Arrest

被引:2
|
作者
Hummel, John [1 ]
Houmsse, Mahmoud [1 ]
Tomassoni, Gery [2 ]
Nair, Devi [3 ]
Romero, Jorge [4 ,5 ]
Hargrove, Joe [3 ]
Mathews, Kiran [6 ]
Thakkar, Anjali B. [7 ]
Ullery, Steven [8 ]
Eapen, Zubin J. [6 ]
Kumar, Uday N. [6 ]
Mehran, Roxana [9 ]
Butler, Javed [10 ,11 ]
机构
[1] Ohio State Univ, Wexner Med Ctr, Columbus, OH USA
[2] Baptist Hlth Lexington, Lexington, KY USA
[3] St Bernards Heart & Vasc Ctr, Jonesboro, AR USA
[4] Harvard Med Sch, Brigham & Womens Hosp, Div Cardiovasc Med, Boston, MA USA
[5] Cardiol & Med Clin, Little Rock, AR USA
[6] Element Sci Inc, San Francisco, CA USA
[7] Univ Calif San Francisco, Dept Med, Div Cardiol, San Francisco, CA USA
[8] NAMSA, Minneapolis, MN USA
[9] Icahn Sch Med Mt Sinai, Zena & Michael A Wiener Cardiovasc Inst, New York, NY USA
[10] Baylor Scott & White Res Inst, 3434 Live Oak St, Dallas, TX 75204 USA
[11] Univ Mississippi, Dept Med, Jackson, MS USA
关键词
machine learning; sudden cardiac arrest; ventricular arrhythmia; wearable cardioverter defibrillator fi brillator; DEATH; PREVENTION; DISEASE;
D O I
10.1016/j.jacc.2024.04.063
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND For many patients, sudden cardiac arrest (SCA) risk is elevated temporarily. Wearable cardioverterdefibrillators (WCDs) can monitor and treat SCA during these temporary periods. Traditional WCDs can be uncomfortable, require frequent maintenance, and cannot be used when showering, resulting in poor compliance and avoidable SCA deaths. The Jewel is a novel, water-resistant patch-wearable cardioverter-defibrillator (P-WCD) with a machine learning detection algorithm designed to improve compliance and protection against SCA. OBJECTIVES This study aims to demonstrate the safety and clinical effectiveness of a novel P-WCD. METHODS The Jewel IDE Study, a prospective, single-arm study conducted at 30 U.S. sites, enrolled patients at SCA risk due to ventricular tachycardia/ventricular fibrillation who were not candidates for or refused an implantable defibrillator. The primary safety endpoint was <15% patients with clinically significant cutaneous adverse device effects and the primary effectiveness endpoint was <2 inappropriate shocks/100 patient-months. Secondary endpoints were >= 1 successful ventricular tachycardia/ventricular fibrillation conversion and wear time compliance of >14.1 h/d. RESULTS A total of 305 patients (mean age: 57.9 years; 30.2% female, 27.9% non-White) were enrolled, of which 290 had available device data. The clinically significant cutaneous adverse device effect rate was 2.30% (upper 1-sided 98% CI: 4.80); none were severe. No device-related deaths or serious adverse events were reported. The inappropriate shock rate was 0.36/100 patient-months (upper 1-sided 98% CI: 1.53). Of 11 shocks in 9 patients, 9 shocks were adjudicated to be appropriate. Eight of 9 shocks were successful with a single shock. Median wear time compliance was 23.5 (20.7-23.9) h/d. CONCLUSIONS The novel P-WCD is a safe and effective WCD with high patient compliance. There were no deaths due to noncompliance and a high number of successful conversions (Jewel IDE study [A Clinical Evaluation of the Jewel P-WCD in Subjects at High Risk for Sudden Cardiac Arrest]; NCT05201495) (J Am Coll Cardiol 2024;84:525-536) (c) 2024 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页码:525 / 536
页数:12
相关论文
共 50 条
  • [31] Implantable Cardioverter-Defibrillator Therapy in a 34-Year-Old Patient with Eating Disorders and after the Third Sudden Cardiac Arrest
    Piotrowicz, Ewa
    Orzechowski, Piotr
    Bilinska, Maria
    Przybylski, Andrzej
    Szumowski, Lukasz
    Piotrowicz, Ryszard
    INTERNATIONAL JOURNAL OF EATING DISORDERS, 2015, 48 (02) : 253 - 257
  • [32] Ventricular arrhythmia burden and implantable cardioverter-defibrillator outcomes in transthyretin cardiac amyloidosis
    Brown, Matthew T.
    Yalamanchili, Sreeram
    Evans, Sean T.
    Ram, Pradhum
    Blank, Evan A.
    Lyle, Melissa A.
    Merchant, Faisal M.
    Bhatt, Kunal N.
    PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY, 2022, 45 (04): : 443 - 451
  • [33] The impact of wearable cardioverter-defibrillator use on long-term decision for implantation of a cardioverter-defibrillator in a semirural acute care hospital
    Anil-Martin Sinha
    Jens Bense
    Wolfgang Hohenforst-Schmidt
    Journal of Interventional Cardiac Electrophysiology, 2021, 62 : 401 - 407
  • [34] Use of the Wearable Cardioverter Defibrillator in High-Risk Cardiac Patients Data From the Prospective Registry of Patients Using the Wearable Cardioverter Defibrillator (WEARIT-II Registry)
    Kutyifa, Valentina
    Moss, Arthur J.
    Klein, Helmut
    Biton, Yitschak
    McNitt, Scott
    MacKecknie, Bonnie
    Zareba, Wojciech
    Goldenberg, Ilan
    CIRCULATION, 2015, 132 (17) : 1613 - 1619
  • [35] Extended use of the wearable cardioverter-defibrittator in patients at risk for sudden cardiac death
    Kutyifa, Valentina
    Vermilye, Katherine
    Daimee, Usama A.
    McNitt, Scott
    Klein, Helmut
    Moss, Arthur J.
    EUROPACE, 2018, 20 : F225 - F232
  • [36] Outcomes After Implantable Cardioverter-Defibrillator Generator Replacement for Primary Prevention of Sudden Cardiac Death
    Madhavan, Malini
    Waks, Jonathan W.
    Friedman, Paul A.
    Kramer, Daniel B.
    Buxton, Alfred E.
    Noseworthy, Peter A.
    Mehta, Ramila A.
    Hodge, David O.
    Higgins, Angela Y.
    Webster, Tracy L.
    Witt, Chance M.
    Cha, Yong-Mei
    Gersh, Bernard J.
    CIRCULATION-ARRHYTHMIA AND ELECTROPHYSIOLOGY, 2016, 9 (03)
  • [37] Celivarone in patients with an implantable cardioverter-defibrillator: Adjunctive therapy for the reduction of ventricular arrhythmia-triggered implantable cardioverter-defibrillator interventions
    Gojkovic, Olivera
    Aliot, Etienne M.
    Capucci, Alessandro
    Connolly, Stuart J.
    Crijns, Harry
    Hohnloser, Stefan H.
    Kulakowski, Piotr
    Roy, Denis
    Radzik, David
    Singh, Bramah N.
    Kowey, Peter R.
    HEART RHYTHM, 2012, 9 (02) : 217 - U2
  • [38] Implantable cardioverter-defibrillator therapy for prevention of sudden death in patients with Arrhythmogenic right ventricular cardiomyopathy/dysplasia
    Corrado, D
    Leoni, L
    Link, MS
    Della Bella, P
    Gaita, F
    Curnis, A
    Salerno, JU
    Igidbashian, D
    Raviele, A
    Disertori, M
    Zanotto, G
    Verlato, R
    Vergara, G
    Delise, P
    Turrini, P
    Basso, C
    Naccarella, F
    Maddalena, F
    Estes, NAM
    Buja, G
    Thiene, G
    CIRCULATION, 2003, 108 (25) : 3084 - 3091
  • [39] Relation of multicenter automatic defibrillator implantation trial implantable cardioverter-defibrillator score with long-term cardiovascular events in patients with implantable cardioverter-defibrillator
    Uslu, Abdulkadir
    Dogan, Cem
    Duman, Hakan
    Tanboga, Ibrahim Halil
    Askin, Lutfu
    Sevimli, Serdar
    NORTHERN CLINICS OF ISTANBUL, 2019, 6 (01) : 40 - 47
  • [40] Cardiac resynchronization therapy in combination with implantable cardioverter-defibrillator
    Daubert, J. Claude
    Leclercq, Christophe
    Mabo, Philippe
    EUROPACE, 2009, 11 : 87 - 92